CYPH
CypherpunkDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The company ended 2025 with $14.0 million of cash, a large ZEC-linked asset position, and management saying available cash should fund at least the next 12 months; if treasury execution holds and biotech optionality is monetized, the stock could re-rate from a depressed base [#10-K-2026-03-16].
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
Board retirements ahead of the 2026 annual-meeting cycle add governance uncertainty [#8-K-2026-04-10].
Momentum
79
Value
41
Sentiment
22
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.90 · Bull $1.35 · Bear $0.45
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $9.00
Why
Momentum79 · Δ7d -
Value41 · Δ7d +0.1
Sentiment22 · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
79
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
22
33% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade D. Momentum 78.7 / Value 41.1 / Sentiment 22.1
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$126.69M
Beta
-0.19
Shares Out
56.65M
P/E (TTM) · Derived
-1.2
P/S (TTM)
-
P/FCF (TTM) · Derived
-1.75
Rev YoY
-
EPS YoY
+81.9%
Gross Margin
-
Op Margin
-
Net Debt
-$47.25M
Current Ratio
1.21
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology